January 2022 pharmaceutical M&A round-up
The first month of the year is often one of the busiest for the announcement of mergers and acquisitions (M&A) in the pharmaceutical sector.
As well as being a busy month for the announcement of licensing agreements and complete response letters, January 2022 has proved fairly significant for M&A deals, with two acquisitions exceeding $1 billion in value.
One was provided by UCB (Euronext: UCB) in its $1.9 billion buy of USA-based biotech Zogenix (Nasdaq: ZGNX) to broaden the Belgian drugmaker's portfolio for rare forms of epilepsy. The other, and the month's biggest deal, was Samsung BioLogics paying $2.3 billion to US biotech Biogen (Nasdaq: BIIB) to take full ownership of the Korean firm's Samsung Bioepis joint venture, which has become one of the world's leading manufacturers of biosimilar drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze